#FGFR2
LightNews LightNews
targetedonc.bsky.social
📢 ICYMI: The #FDA has approved lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally advanced or metastatic #cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.

Read more: targetedonc.com/view/fda-app...

#Oncology #CancerTreatment
FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
targetedonc.com
September 26, 2026 at 4:02 PM
jcb.org
Nita, Bosakova et al. show that the FGFR2 localizes to primary #cilia of developing mouse tissues and in vitro cells; they identify the molecular mechanism of this action, and show its critical function in FGFR2 signaling. rupress.org/jcb/article/...
April 22, 2025 at 2:20 PM
duboisrn.bsky.social
FDA Approves #Lirafugratinib for Previously Treated #FGFR2-Altered #Cholangiocarcinoma: www.pharmacytimes.com/view/fda-app...
FDA Approves Lirafugratinib for Previously Treated FGFR2-Altered Cholangiocarcinoma | Pharmacy Times
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
www.pharmacytimes.com
September 25, 2026 at 12:28 PM
jci.org
Antibodies that suppress tumor growth in a challenging cancer!

This issue’s cover features work by William R. Sellers & team on the identification of biparatopic FGFR2 antibodies that are effective against FGFR2 fusion-driven cholangiocarcinoma: buff.ly/weCpxLs
April 15, 2025 at 4:08 PM
oncodaily.bsky.social
FGFR2-IIIc: Prognostic Biomarker and Resistance Mechanism in Gastric and GEJ Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FGFR2-IIIc #GastricCancer #GEJCancer
FGFR2-IIIc: Prognostic Biomarker and Resistance Mechanism in Gastric and GEJ Cancer - OncoDaily
FGFR2-IIIc: Prognostic Biomarker and Resistance Mechanism in Gastric and GEJ Cancer / cancer, cancer awareness, cancer care, Cancer research, cancer
oncodaily.com
November 9, 2025 at 9:08 PM
dev-journal.bsky.social
FGFR2 directs inhibition of WNT signaling to regulate anterior fontanelle closure during skull development

Read this #OpenAccess Research Article by Lauren Bobzin, Amy Merrill & colleagues:
https://journals.biologists.com/dev/article/152/2/dev204264/365397/
Figure 2 Fgfr2 is required in NCC-derived mesenchyme for closure of the AF. (A-H) HBQ-stained coronal sections at crucial stages of PFS development. (A,B) The ectocranial (ecto) and endocranial (endo) layers of the PFS formed in controls at P5, but only the frontal bone fronts were identified in Wnt1-Cre;Fgfr2−/− mutants. (C,D) At P7, when cartilage (blue) begins to condense in the endocranial layer of the PFS in control, there was no evidence of cartilage in Wnt1-Cre;Fgfr2−/− mice. (E-H) At P11 and P13, when the endocranial cartilage matures and begins to ossify in control, there remained no cartilage in Wnt1-Cre;Fgfr2−/− mutants and the frontal bones were separated by connective tissue. At least four littermate pairs were analyzed per stage. Dashed lines outline frontal bone and osteogenic fronts.
January 22, 2025 at 4:29 PM
thebiotechtimes.bsky.social
Elevar's lirafugratinib (Lyrfigtu) has won FDA approval for FGFR2-rearranged cholangiocarcinoma as a second-line therapy, backed by a 46% confirmed response rate in the ReFocus trial.
Elevar Therapeutics wins FDA approval for Lyrfigtu in bile duct cancer
Lirafugratinib becomes a second-line option for FGFR2-rearranged cholangiocarcinoma after posting a 46% confirmed response rate in the ReFocus trial.
biotech.disruptsmedia.com
September 27, 2026 at 6:22 PM
WO2024002157 - INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF patentscope2.wipo.int/search/en/de... Well, those FGFR2/3 inhibitors look farmiliar, PKMYT1?
January 5, 2024 at 4:35 AM
firstwordgroup.com
Elevar gets US nod for FGFR2-targeted cholangiocarcinoma drug firstwordpharma.com/story/8082548
September 24, 2026 at 4:45 AM
kidneystories.bsky.social
DNA hypermethylation of FGFR2 drives fibrosis in the aging kidney | Scientific Reports - goo.gl/alerts/ZSC9sr #GoogleAlerts
DNA hypermethylation of FGFR2 drives fibrosis in the aging kidney - Scientific Reports
Scientific Reports - DNA hypermethylation of FGFR2 drives fibrosis in the aging kidney
goo.gl
May 2, 2026 at 8:44 AM
genomeweb.bsky.social
FDA Approves Elevar’s Lyrfigtu for FGFR2-Altered Bile Duct Cancer
FDA Approves Elevar’s Lyrfigtu for FGFR2-Altered Bile Duct Cancer
The second-line therapy was approved based on a 46 percent response rate in a Phase I/II trial.
ebx.sh
September 24, 2026 at 2:58 AM
approximately.bsky.social
HLB子会社の胆管癌新薬がFDA承認、株価がストップ高

HLBの米国子会社エレバテラピューティクスが開発したFGFR2標的抗がん剤「リピクトゥ」が、米FDAから胆管癌の2次治療剤として最終品目許可を獲得した。これによりHLBの株価はストップ高となり、グループ銘柄や製薬・バイオセクター全般に好材料として広がった。リピクトゥはFGFR2タンパク質に選択的に作用する経口用新薬である。
出典: mk.co.kr
HLB子会社の胆管癌新薬がFDA承認、株価がストップ高
HLBの米国子会社エレバテラピューティクスが開発したFGFR2標的抗がん剤「リピクトゥ」が、米FDAから胆管癌の2次治療剤として最終品目許可を獲得した。これによりHLBの株価はストップ高となり、グループ銘柄や製薬・バイオセクター全般に好材料として広がった。リピクトゥはFGFR2タンパク質に選択的に作用する経口用新薬である。
www.mk.co.kr
September 28, 2026 at 8:07 AM
jcb.org
FGFR2 residence in primary #cilia is necessary for epithelial #CellSignaling, say Alexandru Nita, Michaela Bosakova and colleagues (Masaryk University): rupress.org/jcb/article/...
April 28, 2025 at 5:56 PM
jcb.org
Spotlight: Kaushik and Ladher @earlab.bsky.social‬ discuss recent work from Nita et al. (rupress.org/jcb/article/...), describing how FGFR2 localization at primary #cilia affects FGFR signaling and highlighting the role of the cilium in a disease-related context. rupress.org/jcb/article/...
June 12, 2025 at 6:22 PM
jcb.org
The primary cilium as a gatekeeper of FGFR2 function. Raman Kaushik and Raj Ladher (@earlab.bsky.social)‬ @ncbsbangalore.bsky.social‬ discuss recent work from Nita et al. (rupress.org/jcb/article/...), in Spotlight: rupress.org/jcb/article/...

#CellSignaling #Development #Disease #Cilia
June 19, 2025 at 2:29 PM
ijosjournal.bsky.social
Why do #coronal sutures sometimes fuse too early? In mice, excessive FGFR2–P38 signaling increased #retinoic acid and premature bone formation. Restoring retinoic acid signaling kept the suture open and improved #neurocognitive outcomes.👇
@ijosjournal.bsky.social
www.nature.com/articles/s41...
August 18, 2026 at 5:07 AM
weldeiry.bsky.social
FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development

aacrjournals.org/cancerres/ar...
FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
Abstract. Activating KRAS mutations are a key feature of pancreatic ductal adenocarcinoma (PDA) and drive tumor initiation and progression. However, mutant KRAS by itself is weakly oncogenic. Defining...
aacrjournals.org
April 22, 2025 at 11:11 PM
sciencedoesrock.bsky.social
The FDA has approved lirafugratinib (Lyrfigtu) for previously treated advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. buff.ly/I603iRj
https://www.labroots.com/trending/biotech-and-pharma/31111/fda-approves-lirafugratinib-advanced-bile-duct-cancer
buff.ly
September 25, 2026 at 5:26 PM
biotech-lr.bsky.social
The FDA has approved lirafugratinib (Lyrfigtu) for previously treated advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. buff.ly/I603iRj
https://www.labroots.com/trending/biotech-and-pharma/31111/fda-approves-lirafugratinib-advanced-bile-duct-cancer
www.labroots.com
September 25, 2026 at 5:26 PM
cancer-lr.bsky.social
The FDA has approved lirafugratinib (Lyrfigtu) for previously treated advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. buff.ly/I603iRj
https://www.labroots.com/trending/biotech-and-pharma/31111/fda-approves-lirafugratinib-advanced-bile-duct-cancer
www.labroots.com
September 25, 2026 at 5:26 PM
drugdiscovery-lr.bsky.social
The FDA has approved lirafugratinib (Lyrfigtu) for previously treated advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. buff.ly/I603iRj
https://www.labroots.com/trending/biotech-and-pharma/31111/fda-approves-lirafugratinib-advanced-bile-duct-cancer
buff.ly
September 25, 2026 at 5:26 PM
immunology-lr.bsky.social
The FDA has approved lirafugratinib (Lyrfigtu) for previously treated advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. buff.ly/I603iRj
https://www.labroots.com/trending/biotech-and-pharma/31111/fda-approves-lirafugratinib-advanced-bile-duct-cancer
www.labroots.com
September 25, 2026 at 5:26 PM
labroots.bsky.social
The FDA has approved lirafugratinib (Lyrfigtu) for previously treated advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. buff.ly/I603iRj
https://www.labroots.com/trending/biotech-and-pharma/31111/fda-approves-lirafugratinib-advanced-bile-duct-cancer
buff.ly
September 25, 2026 at 5:26 PM
healthandmed-lr.bsky.social
The FDA has approved lirafugratinib (Lyrfigtu) for previously treated advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. buff.ly/I603iRj
https://www.labroots.com/trending/biotech-and-pharma/31111/fda-approves-lirafugratinib-advanced-bile-duct-cancer
buff.ly
September 25, 2026 at 5:26 PM
weldeiry.bsky.social
Learning about Lirafugratinib: The First Highly Selective FGFR2 Inhibitor at #GI26
93% of tumors shrunk

Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma
(CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2f/r).
Antoine Hollebecque, MD
Gustave Roussy Cancer Institute
January 9, 2026 at 7:52 PM